Related Experiment Videos
Clinical use of cefuroxime in paediatric community-acquired pneumonia
1Department of General Paediatrics, Hôpital Louis Mourier, Colombes, France.
Insights
Cefuroxime is effective for treating pediatric community-acquired pneumonia (CAP). This review shows intravenous and oral cefuroxime axetil can successfully treat children with varying CAP severity, including severe cases.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Respiratory Medicine
Background:
- Cefuroxime is recommended for community-acquired pneumonia (CAP) by major thoracic societies.
- It exhibits in vitro activity against common CAP bacterial pathogens.
- Adjunctive therapy is needed for atypical pathogens like Mycoplasma, Chlamydia, or Legionella.
Purpose of the Study:
- To review clinical experience with cefuroxime in treating pediatric bacterial pneumonia.
- To evaluate the efficacy of intravenous and oral cefuroxime axetil in children.
- To assess treatment strategies for varying severities of pediatric CAP.
Main Methods:
- Systematic review of clinical data on cefuroxime use in pediatric pneumonia.
- Analysis of treatment outcomes for intravenous and oral cefuroxime axetil.
- Evaluation of sequential therapy from intravenous to oral administration.
Main Results:
- Intravenous cefuroxime is effective for severe pediatric pneumonia, including complicated cases.
- Children with stabilizing pneumonia can transition from IV to oral cefuroxime axetil within 24-72 hours.
- Oral cefuroxime axetil is suitable for milder pediatric pneumonia cases, whether inpatient or outpatient.
Conclusions:
- Cefuroxime, particularly cefuroxime axetil, is a viable treatment option for pediatric bacterial pneumonia.
- Sequential therapy (IV to oral) is an effective strategy for hospitalized children.
- Treatment can be tailored to disease severity, allowing for outpatient management of milder cases.
Abstract:
Cefuroxime has been recommended as a component of treatment for community-acquired pneumonia (CAP) in guidelines produced by several groups, including the US and British Thoracic Societies. It is effective in vitro against the major bacterial pathogens in CAP but it needs to be given with an agent that is active against Mycoplasma, Chlamydia or Legionella spp. if the presence of any of these organisms is suspected. Cefuroxime penetrates respiratory tissue effectively after either parenteral or oral administration, and it has a pharmacodynamic profile which suggests that adequate cover can be achieved with oral therapy for respiratory pathogens susceptible to cefuroxime concentrations of 4 mg/L or less. This break-point is applicable to oral monotherapy and to sequential therapy regimens for the treatment of pneumonia. Cefuroxime can be used either orally or parenterally and it is approved in many countries for the treatment of adult pneumonia by either route. The oral form, cefuroxime axetil, has been used extensively in the treatment of children aged over 3 months but its use in paediatric pneumonia has not been reviewed. The present review summarises clinical experience in the treatment of bacterial pneumonia, of varying severity, in children. The data show that children with severe pneumonia, including those with pleural effusion or complications, can be treated with a full course of intravenous cefuroxime therapy, whereas hospitalised children whose pneumonia stabilises rapidly after initial intravenous therapy can change to oral cefuroxime axetil after 24 to 72 hours and may be able to return home. Oral cefuroxime axetil was appropriate for patients with milder pneumonia managed either in hospital or at home.